Q-omics provides the consensus-scored TMEM82 profile across patient tissues and cancer cell-line models. TMEM82 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, TMEM82 is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, TMEM82 RNA expression shows 14,374 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight KIRP, COAD, and ESCA as cancer lineages where TMEM82 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM82 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM82 survival associations across molecular data types. TMEM82 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (8) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM82 RNA expression–survival associations across cancer types. High TMEM82 expression shows unfavorable associations in CESC, but favorable associations in KIRP, KIRC, HNSC, READ and SCLC. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for TMEM82 RNA expression.
This table summarizes TMEM82 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 1. The strongest signals are observed in COAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TMEM82. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM82 shows lower tumor expression in COAD, KICH, LIHC, READ and KIRP and higher tumor expression in LUAD. The COAD box plot shows higher TMEM82 RNA expression in normal versus tumor tissue (log2 FC = −3.163, t-test p < 0.001).
This table shows molecular features associated with TMEM82 in patient tissues and cancer cell lines. In patient samples, TMEM82 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM82 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
